The of­fer does­n't stop at Covid. No­var­tis opens up man­u­fac­tur­ing ops to make Caris­ma’s CAR-M cell ther­a­py

No­var­tis is dou­bling down on its con­tract man­u­fac­tur­ing busi­ness.

The phar­ma gi­ant lent a hand to Pfiz­er and BioN­Tech last year, de­ploy­ing fill-fin­ish sites in Switzer­land and Slove­nia to sup­port large-scale pro­duc­tion of their mR­NA Covid-19 vac­cine.

This time around, No­var­tis is re­serv­ing its cell and gene fa­cil­i­ty in Mor­ris Plains, NJ for Caris­ma Ther­a­peu­tics, whose HER2-tar­get­ed CAR-M cell ther­a­py is be­ing test­ed in ini­tial tri­als for sol­id tu­mors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.